AIR ALLERGY(TM) by AirWare Labs Selected as a 2014 Visionary Award Finalist for the VISION(R) Consumer Products Conference

AIR ALLERGY(TM) by AirWare Labs Selected as a 2014 Visionary Award Finalist for 
the VISION(R) Consumer Products Conference 
Patented Flu and Allergy-Blocking Nasal Filter Selected by INDA, the
Association of the Nonwoven Fabrics Industry, to Present at VISION(R)
in Dallas, January 27-30 
SCOTTSDALE, AZ -- (Marketwired) -- 01/27/14 --  AirWare Labs Corp.
(OTCQB: AIRW) today announced that its AIR ALLERGY(TM) Advanced Nasal
Filter has been selected as a 2014 Visionary Award Finalist for the
VISION(R) Consumer Products Conference in Dallas, January 27-30,
2014. 
Chosen by INDA, the Association of the Nonwoven Fabrics Industry, for
its "demonstrated uniqueness, novelty and technical sophistication,"
the AIR ALLERGY(TM) patented nasal filter design effectively blocks
airborne allergens like pollen, dust and pet dander, as well as
bacteria and viruses that cause the flu by entering the body through
the nasal passage. 
"We are thrilled that AIR ALLERGY(TM) was selected by INDA as a
Visionary Award finalist," said Jeffrey Rassas, President and CEO of
AirWare Labs. "This prestigious nomination is a testimony of our
commitment to using cutting-edge design in the development of easy to
use products that enhance health, vitality -- and life overall -- by
promoting optimal breathing."  
AirWare Labs Director of Marketing, Chase Herschman will give a
presentation to VISION(R) attendees on the unique design and
application of the AIR ALLERGY(TM) filter and its impact on the
health and wellness industry, particularly as demand for products
that defend against allergies and flu are at record levels.  
In fact, market research firm Mintel recently reported that the cold,
flu and allergy remedies market increased 22% from 2007-2012, with 7%
of this growth happening between 2010 and 2012 -- due in large part
to a severe 2012 allergy season. Mintel expects cold, flu and allergy
sales to continue to climb as a result of the current cycle of milder
temperatures and increased pollen counts. 
In addition, Mintel notes an increasing demand for natural or
alternative choices versus traditional medications for colds, flus
and allergies. With its use of eucalyptus essential oil as a natural
antibiotic defense against airborne allergens, viruses and bacteria,
AIR ALLERGY(TM) is well positioned to capture a prominent place in
this growing market, as reflected in its 2013 national rollout into
7,500 Walgreen's stores. 
About AirWare Labs Corporation: 
AirWare Labs Corp. [publicly traded as (OTCQB: AIRW)] provides
patented and innovative technology solutions for consumer products
that promote better health through breathing and enhanced wellbeing.
AirWare Labs' products are marketed under the brand name of AIR(R).
AIR(R) products utilize an FDA approved medical grade silicone,
molded as an intranasal Air Breathe dilator, to act as the delivery
system. This AIR(R) microstructure enhances normal nasal airflow with
every breath -- clinically proven to deliver up to 40% more oxygen.  
Some AIR(R) products are infused with essential oils with unique
healing properties including antibacterial and therapeutic defense
against airborne allergens, viruses and bacteria. AIR(R) Allergy and
Travel products provide additional defense in the form of an
integrated filter media from 3M to remove microscopic particles that
carry viruses, allergens and bacteria. Other AIR(R) specialty
products help provide and performance enhancements and relief from
congestion, insomnia, headaches, nausea, and snoring. For more
product information, please visit: http://www.airwarelabs.com or
company information visit: http://airwarelabscorp.com. 
Forward-Looking Statement: The statements in this press release
regarding any implied or perceived benefits from the release by
AirWare Labs Corp. of its AIR ALLERGY(TM) product are forward-looking
statements. Such statements involve risks and uncertainties,
including, but not limited to, risks and effects of legal and
administrative proceedings and governmental regulation, especially in
a foreign country, future financial and operational results,
competition, general economic conditions, and the ability to manage
and continue growth.  
Should one or more of these risks or uncertainties materialize, or
should underlying assumptions prove incorrect, actual outcomes may
vary materially from those indicated. Important factors that could
cause actual results to differ materially from the forward-looking
statements we make in this news release include the introduction of
new technology, market conditions and those set forth in reports or
documents we file from time to time with the SEC. We undertake no
obligation to revise or update such statements to reflect current
events or circumstances after the date hereof or to reflect the
occurrence of unanticipated events. 
Media Contact: 
Jennifer Breitegan
480-528-7870
jen@kwprgroup.com 
Investor Relations:
Jeffrey Rassas
480-463-4246